Possible luteolytic effects of luteinizing hormone-releasing hormone in normal women
- PMID: 369890
- DOI: 10.1016/s0015-0282(16)43755-6
Possible luteolytic effects of luteinizing hormone-releasing hormone in normal women
Abstract
The administration of five subcutaneous 250-microgram doses of lutienizing hormone (LH)-releasing hormone (LHRH) at 4-hour intervals, the first injection being given at 8 A.M. on 1 or 2 consecutive days between days 1 and 9 following the LH surge in normal women, shortened the luteal phase from 1 to 4 days in 16 of 17 treatment cycles. There was a better efficiency of treatment when LHRH was administered on days 6 to 9 after the LH surge as compared with days 1 to 5. In fact, the luteal phase was shortened from 3.3 +/- 0.2 days versus 1.4 +/- 0.2 days (P less than 0.01) and the serum progesterone level was decreased to 44% +/- 6% versus 71% +/- 6% of control levels (P less than 0.01) when the neurohormone was injected late as compared with early in the luteal phase. The present data raise the possibility of a luteolytic effect of LHRH in normal women and indicate the interest of such a near-physiologic approach for the control of luteal function and time of appearance of menses.
Similar articles
-
Luteolytic activity of LHRH and [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide: a new and physiological approach to contraception in women.Int J Fertil. 1980;25(3):203-12. Int J Fertil. 1980. PMID: 6108931
-
Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women.Fertil Steril. 1990 Nov;54(5):805-10. Fertil Steril. 1990. PMID: 2226914 Clinical Trial.
-
Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.Endocrinology. 1987 Aug;121(2):612-8. doi: 10.1210/endo-121-2-612. Endocrinology. 1987. PMID: 3109885
-
Luteolytic effect of intranasal administration of [D-Ser(TBU)6,DES-Gly-NH2(10)]-luteinizing hormone-releasing hormone ethylamide in normal women.Fertil Steril. 1979 Dec;32(6):646-51. doi: 10.1016/s0015-0282(16)44412-2. Fertil Steril. 1979. PMID: 389676
-
Gonadotropin-releasing hormone antagonists: effects on the ovarian follicle and corpus luteum.Clin Obstet Gynecol. 1993 Sep;36(3):744-52. doi: 10.1097/00003081-199309000-00031. Clin Obstet Gynecol. 1993. PMID: 8403621 Review. No abstract available.
Cited by
-
Similar luteinizing hormone-releasing hormone binding sites in rat anterior pituitary and ovary.Proc Natl Acad Sci U S A. 1980 Sep;77(9):5567-71. doi: 10.1073/pnas.77.9.5567. Proc Natl Acad Sci U S A. 1980. PMID: 6254091 Free PMC article.
-
Effect of chronic treatment with [D-Ala6, des-Gly-NH210]LHRH ethylamide on ovarian histology in the rat.Cell Tissue Res. 1982;227(1):213-9. doi: 10.1007/BF00206342. Cell Tissue Res. 1982. PMID: 6756639
-
Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion.J Clin Invest. 1984 Jun;73(6):1638-47. doi: 10.1172/JCI111370. J Clin Invest. 1984. PMID: 6427277 Free PMC article.
-
LRFD6a has a dose-related stimulatory or inhibitory effect on the ovary in normal luteal phase women.J Endocrinol Invest. 1985 Aug;8(4):297-302. doi: 10.1007/BF03348501. J Endocrinol Invest. 1985. PMID: 3934254
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources